Pulmonx Corp
LUNG Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$1.95
KIRA · Stoqly’s AI analyst, in plain words
- Pulmonx Corp had $90.5M of revenue in fiscal 2025, up 8.0% on the year before. Over five years, revenue changed +22.6% a year on average.
- Its operating margin was −59.3%, up 9.6 pts: of every 100 in sales, about −59 is left after running the business.
- Pulmonx Corp lost $54.0M in fiscal 2025.
- Free cash flow was −$32.8M in fiscal 2025, −36.3% of revenue.
- Pulmonx Corp has $32.6M more cash than debt.
Market cap
$82.8M
P/E
—
Revenue
$90.5M
Net income
−$54.0M
Free cash flow
−$32.8M
Operating margin
−59.3%
Pulmonx Corp in 30 seconds · fiscal 2025
Are sales growing?
+8.0%
Yes. Sales grew 8.0% last year.
Does it make a profit?
−59.7%
No. It lost money last year.
Does profit turn into cash?
−36.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Pulmonx Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- Pulmonx Corp
- CIK
- 0001127537
Pulmonx Corp · LUNG
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $48.4M | $53.7M | $68.7M | $83.8M | $90.5M |
| Revenue growth | 47.9% | 10.8% | 28.0% | 22.0% | 8.0% |
| Gross margin | 73.6% | 74.3% | 73.9% | 74.0% | 74.2% |
| Operating margin | −97.7% | −109.3% | −90.2% | −68.9% | −59.3% |
| Net income | −$48.7M | −$58.9M | −$60.8M | −$56.4M | −$54.0M |
| Net margin | −100.5% | −109.8% | −88.6% | −67.3% | −59.7% |
| Diluted EPS | −$1.35 | −$1.59 | −$1.60 | −$1.44 | −$1.33 |
| Cash | |||||
| Cash from operations | −$41.4M | −$45.1M | −$37.6M | −$31.5M | −$32.4M |
| Capital expenditure | $3.7M | $1.3M | $0.8M | $1.4M | $0.5M |
| Free cash flow | −$45.1M | −$46.4M | −$38.4M | −$33.0M | −$32.8M |
| FCF margin | −93.1% | −86.5% | −55.9% | −39.4% | −36.3% |
| Share buybacks | $0.0M | $0.0M | $0.0M | — | — |
| Share count change | 254.7% | 2.7% | 2.4% | 3.0% | 4.0% |
| Debt and strength | |||||
| Cash and short-term investments | $180M | $141M | $83.5M | $70.9M | $69.8M |
| Debt incl. finance leases | $17.5M | $17.4M | $39.4M | $40.4M | $37.2M |
| Shareholders' equity | $193M | $154M | $118M | $85.8M | $54.1M |
| Current ratio | 11.9x | 9.1x | 6.5x | 5.6x | 5.1x |
| Interest coverage | −57.1x | −55.0x | −19.2x | −16.5x | −17.0x |
| Returns and quality | |||||
| Return on capital | −121.7% | −153.0% | −66.0% | −82.5% | −196.6% |
| Return on equity | −23.2% | −33.9% | −44.7% | −55.3% | −77.2% |
| Return on tangible equity | −25.5% | −38.9% | −52.5% | −67.6% | −104.3% |
| Piotroski F-score | 3 | 3 | 2 | 3 | 3 |
| Altman Z'' | 4.8 | 1.2 | −3.1 | −6.1 | −11.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.5M
5 insiders
Of sales under plans
8%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pulmonx Corp · LUNG
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.95 a share, the company is worth $82.8M.
Source: SEC EDGAR XBRL filings (CIK 0001127537). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.